Agota Apati | Stem Cell Based Disease Modelling | Best Researcher Award

Dr. Agota Apati | Stem Cell Based Disease Modelling | Best Researcher Award

Dr. Ágota Apáti, PhD, DSc, is a distinguished Hungarian molecular biologist and Senior Research Associate at the Institute of Molecular Life Sciences, Research Centre for Natural Sciences. She leads the Pluripotent Stem Cell Laboratory and is renowned for establishing Hungary’s first human pluripotent stem cell lab. With over 70 publications and an H-index of 25, her work is widely recognized internationally. Dr. Apáti’s research encompasses human iPSC-derived disease models, membrane transporters, and cellular signaling pathways, with implications in schizophrenia, diabetes, and rare syndromes. She has supervised numerous PhD students and maintains active roles in both national and international scientific societies. Her commitment to translational stem cell research and ethical scientific practice positions her as a leading figure in the field of regenerative medicine and cellular therapeutics.

Profile

🎓 Education

Dr. Ágota Apáti holds a Master of Science (MSc) degree in Chemistry from Eötvös Loránd University of Sciences, Budapest (1984–1989). She later pursued doctoral studies and earned her PhD from Semmelweis Medical University (1998–2003), focusing on molecular and cellular aspects of hematology and immunology. Her academic training blends rigorous biochemical education with advanced medical sciences, establishing a solid foundation for her research career in stem cell biology and cellular therapeutics. Through continuous engagement in teaching and supervising graduate students, she has also remained an integral part of academic development at Hungary’s premier institutions. Her strong interdisciplinary background supports her work on complex cellular processes and disease modeling, and she is also a Doctor of Science (DSc, 2024) from the Hungarian Academy of Sciences—an honor awarded for substantial contributions to biomedical research in Hungary.

🧪 Experience

With over three decades of research experience, Dr. Ágota Apáti began her scientific career as a Research Fellow at Semmelweis Medical University (1989–1993). She progressed through multiple institutions, including the National Institute of Haematology and Immunology (1993–2004) and the National Blood Service (2005–2013), where she led various molecular biology projects. Between 2013 and 2023, she was a Senior Research Associate and lab head at the Institute of Enzymology, Hungarian Academy of Sciences. Since 2023, she continues her leadership as Laboratory Head at the Institute of Molecular Life Sciences under HUNREN. She has consistently taught and mentored postgraduate students in biochemistry, hematology, immunology, and membrane biology. Dr. Apáti’s collaborative and interdisciplinary projects have helped develop multiple disease models and cellular assays. Her scientific leadership has been instrumental in expanding Hungary’s role in cutting-edge stem cell research and molecular diagnostics.

🏅 Awards and Honors

Dr. Ágota Apáti has been recognized both nationally and internationally for her contributions to biomedical research. Early in her career, she received the prestigious UNIDO award during the ICRO course on RNA structure and function in Trieste, Italy (1994). In 2024, she was awarded the Doctor of Science (DSc) degree by the Hungarian Academy of Sciences—a distinguished title granted to researchers with a substantial, impactful body of scientific work. Her membership in renowned scientific organizations, such as the International Society for Stem Cell Research (ISSCR), Hungarian Society of Biology, Hungarian Society of Biochemistry, and the Hungarian Medical Research Council’s Ethical Board for Human Reproduction, underscores her stature in the field. These accolades not only reflect her scientific excellence but also her contributions to ethical research practice, public health, and mentoring within the scientific community, cementing her reputation as a key contributor to molecular life sciences.

🔬 Research Focus

Dr. Apáti’s research centers on pluripotent stem cells, disease modeling, and cellular signaling. She specializes in generating and differentiating human induced pluripotent stem cells (iPSCs) into neuronal, cardiac, mesenchymal, and endothelial lineages. Her work extends into disease modeling for schizophrenia, arteriosclerosis, diabetes, DiGeorge syndrome, and Frank-Ter Haar syndrome using patient-derived iPSC lines and CRISPR-based genome editing. She has developed cellular reporter systems to study membrane transporter function and calcium signaling pathways, significantly advancing understanding in neuropsychiatric and cardiovascular disorders. Through integrative omics and 3D organoid models, Dr. Apáti’s lab explores metabolic and genetic dysregulation in human pathologies. Her translational research aims to identify drug targets and therapeutic strategies using patient-specific cell lines. She also investigates multidrug resistance in stem cells and cancer, contributing to better clinical interventions. Her multidisciplinary projects bridge fundamental biology with clinical relevance, making her a vital contributor to regenerative medicine and personalized therapy.

Conclusion

Dr. Ágota Apáti is a trailblazing scientist whose pioneering work in human stem cell research, disease modeling, and membrane biology continues to shape translational medicine, with a sustained commitment to research excellence, scientific mentorship, and ethical innovation in biomedical sciences.

Publications

  • Haloperidol, Olanzapine, and Risperidone Induce Morphological Changes in an In Vitro Model of Human Hippocampal Neurogenesis

    Biomolecules
    2024-06 | Journal article | Author
    CONTRIBUTORS: Bálint Jezsó; Sára Kálmán; Kiara Gitta Farkas; Edit Hathy; Katalin Vincze; Dzsenifer Kovács-Schoblocher; Julianna Lilienberg; Csongor Tordai; Zsofia Nemoda; László Homolya et al.
  • Partial Disturbance of Microprocessor Function in Human Stem Cells Carrying a Heterozygous Mutation in the DGCR8 Gene

    Genes
    2022-10 | Journal article | Author
    CONTRIBUTORS: Dóra Reé; Ábel Fóthi; Nóra Varga; Orsolya Kolacsek; Tamas Orban; Agota Apat
  • A Novel Cell-Based Model for a Rare Disease: The Tks4-KO Human Embryonic Stem Cell Line as a Frank-Ter Haar Syndrome Model System

    International Journal of Molecular Sciences
    2022-08 | Journal article | Author
    CONTRIBUTORS: Loretta László; Hédi Maczelka; Tamás Takács; Anita Kurilla; Álmos Tilajka; László Buday; Vas Virag; Agota Apati
  • Synthesis and Systematic Investigation of Lepidiline A and Its Gold(I), Silver(I), and Copper(I) Complexes Using In Vitro Cancer Models and Multipotent Stem Cells

 

Mai Osman Mohamed Kadry | Biochemistry | Best Researcher Award

Assist. Prof. Dr. Mai Osman Mohamed Kadry | Biochemistry | Best Researcher Award

Assist. Prof. Dr. Mai O.Kadry,National Research Center, Egypt

Dr. Mai Osman Mohamed Kadry is a distinguished biochemistry researcher at the Therapeutic Chemistry Department, National Research Centre, Egypt. With a Doctorate in Biochemistry from Cairo University (2016), her work focuses on oxidative injury, nanotoxicity, and cancer therapy. She has published extensively in high-impact journals on topics like antioxidant effects, stem cell therapies, and metabolic disorders. Dr. Kadry has also contributed to academia, teaching pharmacognosy at 6th October University. Skilled in advanced techniques like PCR, HPLC, and ELISA, she actively participates in groundbreaking nanobiotechnology research projects. Dr. Kadry is committed to advancing therapeutic strategies for critical diseases. 📚🧬

Profile

🎓 Education

Assist. Prof. Dr. Mai O. Kadry boasts a strong academic foundation in pharmaceutical sciences. She earned her Doctorate in Biochemistry from the Faculty of Pharmacy, Cairo University, in 2016, with a thesis on the “Amelioration of Nano-Sized Titanium Dioxide-Induced Oxidative Injury in Mice by Some Antioxidants.” She obtained her Master’s degree in Pharmaceutical Sciences from Helwan University in 2008, focusing on the synergistic effects of phytic and catechin on carbon tetrachloride-induced damage in rats. Dr. Kadry completed her B.Sc. in Pharmaceutical Science at Ain Shams University in 2003, graduating with honors. She also attended English language schools, enhancing her global communication skills. 🌟🔬

🧪 Experience

Assist. Prof. Dr. Mai O. Kadry has accumulated valuable experience in academia and research. She served as a pharmacognosy instructor at the Faculty of Pharmacy, 6th October University, Cairo, Egypt (2003–2004), where she effectively delivered courses on natural products and their therapeutic applications. Dr. Kadry also contributed as a staff member focused on development and quality enhancement, aligning with the standards of the National Commission for Academic Accreditation. Her dedication to education and quality assurance reflects her commitment to fostering academic excellence and professional growth in pharmaceutical sciences. 📚🔬

Training 🧬📚

Assist. Prof. Dr. Mai O. Kadry has undergone extensive training in various scientific disciplines. She completed courses in Biostatistics (November 2016) and Bioinformatics (January 2017) at the National Research Centre. Earlier, she gained expertise in Scientific Typewriting Bases (March 2007) and Occupational Health and Safety (June 2009). Additionally, she mastered Protein Electrophoresis through a four-month course in 2006. Dr. Kadry enhanced her practical skills with hands-on training at Al-Borg Clinical Laboratory, focusing on PCR techniques for detecting HBV and HCV at the Theodor Bilharz Research Institute. Her comprehensive training equips her with valuable laboratory and analytical skills. 🔬🧪

🔬 Research Focus

Assist. Prof. Dr. Mai O. Kadry focuses on cutting-edge biomedical research, emphasizing toxicity, cancer therapy, and molecular biology. Her work explores inflammatory mediators, DNA damage, and therapeutic approaches in liver, brain, and nephrotoxicity contexts. She investigates autophagy, necroptosis, and novel strategies like resveratrol nano-formulations for ovarian cancer. Dr. Kadry also studies molecular pathways in gastric and prostate cancers, including miRNA-lncRNA signaling and CRISPR-Cas9 applications. Other interests involve genetic mutations in leukemia, drug-delivery systems, and nanotechnology for breast cancer. Her contributions bridge diagnostics, therapeutic innovations, and cellular mechanisms in oncology and toxicology. 🔬✨

Conclusion

Assist. Prof. Dr. Mai O. Kadry is a distinguished biochemistry researcher whose work bridges advanced molecular biology and therapeutic innovation. With expertise in nanotoxicity, oxidative injury, and cancer therapy, she contributes significantly to biomedical science through impactful research and academic leadership. Her training in cutting-edge techniques and her focus on translational medicine position her at the forefront of scientific discovery. Dr. Kadry’s dedication to improving healthcare through targeted therapies and her commitment to academic excellence make her a valuable asset to the scientific community. Her career reflects passion, innovation, and a relentless pursuit of better treatment solutions.

 

Publications
  • Collaboration of Hprt/K-RAS/c-Myc mutation in the oncogenesis of T-lymphocytic leukemia: a comparative study

    Future Science OA
    2024-12-31 | Journal article
    CONTRIBUTORS: Mai O Kadry; Abdel-Hamid Z Abdel Hamid; Rehab M Abdel-Megeed
  • Fischer’s oligopeptide ratio in ischemic hypoxia: prophylactic amendment of sophoretin and melatonin supplementation

    Future Science OA
    2024-12-31 | Journal article
    CONTRIBUTORS: Mai O Kadry; Hanaa Mahmoud Al
  • Thioctic acid shield against lipopolysaccharide depression and endoplasmic reticulum stress: GR7M/Homer/ATF6 signaling

    Future Science OA
    2024-12-31 | Journal article
    CONTRIBUTORS: Mai O. Kadry; Rehab M. Abdel-Megee